Opportunity

Simpler Grants.gov #PAR-26-126

Management and Data Coordination Services for Pancreatic Cancer Detection Consortium

Buyer

National Cancer Institute (NCI)

Posted

February 11, 2026

Respond By

July 01, 2026

Identifier

PAR-26-126

NAICS

541715

This opportunity seeks to establish a Management and Data Coordination Unit (MDCU) for the Pancreatic Cancer Detection Consortium (PCDC) under the National Cancer Institute (NCI): - Government Buyer: - National Cancer Institute (NCI), part of the National Institutes of Health - OEMs and Vendors: - No specific OEMs or vendors are named in this solicitation - Services Requested: - Establishment and operation of the MDCU for the PCDC - Key services include: - Study design and protocol development - Statistical analysis and data management - Coordination of consortium activities - Support for biorepository building - Organizational and logistical support for PCDC research - Unique or Notable Requirements: - Focus on early detection of pancreatic ductal adenocarcinoma and precursor lesion characterization - Open to a wide range of eligible applicants (government, nonprofits, businesses, educational institutions, and others) - No products or hardware are being procured; only specialized research coordination and management services are required - Place of Performance: - National Cancer Institute (NCI) is the contracting office; specific performance locations are not detailed

Description

The National Cancer Institute (NCI) is soliciting applications for the establishment of the Management and Data Coordination Unit (MDCU) as part of the Pancreatic Cancer Detection Consortium (PCDC). The MDCU will support collaborative efforts including study design, protocol development, statistical analysis, coordination, and data management. It will also coordinate biorepository building and provide organizational and logistical support for PCDC activities. The PCDC aims to conduct research on early detection of pancreatic ductal adenocarcinoma and characterization of its precursor lesions to identify high-risk patients.

View original listing